Cerca
Items 1-8 di 8
Accelerated bone mass senescence after hematopoietic stem cell transplantation
(2013)
Osteoporosis and avascular necrosis
(AVN) are long-lasting and debilitating complications of hematopoietic stem cell transplantation
(HSCT).
We describe the magnitude of bone loss, AVN
and impairment in osteogenic ...
Immunological derangement in Hypocellular Myelodysplastic Syndromes
(2014)
Hypocellular or hypoplastic myelodysplastic syndromes (HMDS) are a distinct subgroup accounting for 10–15% of all MDS patients, that are characterized by the presence of bone marrow (BM) hypocellularity, various degree of ...
OPSI threat in hematological patients
(2013)
Overwhelming post-splenectomy infection (OPSI) is a rare medical emergency, mainly caused by encapsulated bacteria, shortly progressing from a mild flu-like syndrome to a fulminant, potentially fatal, sepsis. The risk of ...
Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
(2016)
The urokinase (uPA)-type
plasminogen activator receptor (uPAR) is a GPIanchored receptor that focuses urokinase (uPA)
proteolytic activity on the cell surface. uPAR also
regulates cell adhesion, migration and ...
In vitro apoptotic effects of farnesyltransferase blockade in acute myeloid leukemia cells
(2016)
Farnesyltransferase inhibitors (FTIs)
are a class of oral anti-cancer drugs currently tested
in phase I-II clinical trials for treatment of
hematological malignancies. The in vitro effects of
various FTIs (alpha-hydr ...
67 kDa laminin receptor (67LR) in normal and neoplastic hematopoietic cells: is its targeting a feasible approach?
(2016)
The 67 kDa laminin receptor (67LR)
is a non-integrin cell surface receptor for laminin
(LM) that derives from a 37 kDa precursor (37LRP).
67LR expression is increased in neoplastic cells and
correlates with an enhanced ...
Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment
(2016)
T-large granular lymphocyte
leukemia (T-LGLL) is a chronic clonal proliferation
of effector memory cytotoxic CD3+CD57+CD56- T
cells and the current guidelines suggest
immunosuppressive therapy as first-line therapy, ...
A Case Series of Blastic Plasmacytoid Dendritic Cell Neoplasia
(2020)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare and aggressive tumor, derives from plasmacytoid dendritic cell precursors and is characterized by CD4 and CD56 positivity accompanied by the expression ...